Trial Profile

Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Intravenous Eravacycline in Pediatric Patients From 8 Years to Less Than 18 Years of Age With Complicated Intra-abdominal Infections (cIAI)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 04 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eravacycline (Primary)
Indications Appendicitis; Cholecystitis; Gastric perforation; Intestinal perforation; Intra-abdominal infections; Liver abscess; Peritonitis
Focus Adverse reactions
Sponsors Innoviva Specialty Therapeutics

26 Jun 2025 Planned End Date changed from 31 Oct 2029 to 19 Mar 2029.
26 Jun 2025 Planned primary completion date changed from 31 Oct 2029 to 3 Mar 2029.
04 Jun 2025 Planned End Date changed from 2 Feb 2026 to 31 Oct 2029.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com